Percutaneous ethanol instillation therapy for hepatocellular carcinoma - a randomized controlled trial

摘要: BACKGROUND AND AIMS: The aim of the study was to compare clinical outcome additional percutaneous ethanol instillation (PEI) against no further treatment in patients with hepatocellular carcinoma receiving hormonal long-acting octreotide. METHODS: In a randomized controlled trial conducted tertiary care center, total 61 inoperable were treated octreotide 30 mg i.m. once month and randomly assigned receive either PEI (31 patients) or (30 patients). RESULTS: Median survival time did not significantly differ between plus group (14 months; 95% CI: 9–28 months) alone (22 10–30 (logrank test P = 0.9). Similarly, an analysis stratifying for tumor diameter (< 5 cm 5–8 cm) showed significant differences non-PEI 0.68). Progression-free according RECIST similar two groups (median: 3 months [3–6 CI] vs. 6 [3–7 CI], logrank 0.63). Time local control (6 months). course alpha-fetoprotein levels reported quality life groups. CONCLUSIONS: addition result better overall survival, longer progression-free control.